Clorox Q1 FY2027 Earnings: Sales Rise as Cost Pressure Narrows Gross Margin

Clorox (NYSE: CLX) reported fiscal Q1 2027 net sales of $1.905 billion, up 33% year over year, while diluted EPS rose 114% to $1.39 from $0.65. GOJO and the comparison with the prior-year ERP-related inventory drawdown drove most of the sales increase, while higher commodity, manufacturing and logistics costs reduced gross margin.

Core Earnings Data

Reported sales growth included approximately 15 percentage points from the GOJO acquisition. Organic sales increased 18%, although Clorox said about 18 points of that growth reflected lapping the ERP-related inventory drawdown in the prior-year quarter.

Adjusted EPS increased 82% as higher sales, cost savings and a lower tax rate outweighed cost inflation. GAAP EPS also benefited from the absence of the prior-year digital capabilities and productivity investment, partly offset by GOJO acquisition and integration costs.

Adjusted EPS and organic sales are non-GAAP measures. Operating cash flow is year-to-date through the end of the first quarter.

Business and Segment Performance

All four reportable segments increased sales and adjusted EBIT. Health and Wellness recorded the largest growth, with GOJO contributing approximately 39 percentage points to its 62% sales increase, while the other U.S. segments primarily benefited from lapping the ERP inventory drawdown.

Health and Wellness organic sales rose 23%, compared with reported growth of 62%. International provided a clearer view of operating demand: organic sales increased 9%, supported by higher shipments across several regions, particularly Latin America.

Profitability, Cash Flow and Balance Sheet

Gross margin contracted despite higher volume and cost savings because commodity, manufacturing and logistics expenses increased. GOJO inventory step-up accounting reduced reported gross margin by about 50 basis points. Excluding acquisition and integration costs, adjusted gross margin was 40.9% and adjusted gross profit was $780 million.

Selling and administrative expenses were $290 million, or 15.2% of sales. Excluding $16 million of acquisition and integration expenses, adjusted selling and administrative costs were $274 million, or 14.4% of sales. Interest expense increased to $52 million from $23 million, creating an additional offset to the operating profit improvement.

First-quarter operating cash flow rose to $143 million from $93 million. Cash and equivalents increased to $184 million from $143 million at June 30, while inventory was broadly stable sequentially at $774 million. At quarter-end, Clorox had $1.175 billion of notes and loans payable and $3.982 billion of long-term debt.

ERP Comparisons and GOJO Lifted Growth as Inflation Weighed on Margin

The composition of growth is central to interpreting the quarter. GOJO accounted for about 15 points of the 33% reported sales increase, while the ERP comparison contributed about 18 points to organic growth. Clorox therefore generated most of the headline increase through the acquisition and the reversal of a prior-year shipment disruption rather than a broad acceleration in the existing business.

The same comparison affected earnings. Clorox estimated that the prior-year ERP inventory drawdown reduced adjusted EPS by about $0.90, making the fiscal Q1 2027 growth rate easier to achieve. At the same time, the 130-basis-point gross margin decline shows that higher sales and cost savings did not fully absorb current commodity and operating cost pressure.

FY2027 Guidance

Clorox maintained its full-year sales and EPS ranges. However, it updated its gross margin and selling and administrative expense assumptions after the cost environment became more challenging, and management now expects adjusted EPS to finish closer to the low end of the existing range.

The GAAP EPS outlook includes approximately $0.29 per share of GOJO transaction-related costs. Advertising and sales promotion spending remains expected at about 10% of sales, and the effective tax rate remains projected at about 23%.

Management View

Chair and CEO Linda Rendle attributed the quarter to execution and timing benefits but said inflationary pressure had increased. Management plans to use cost savings and pricing actions to mitigate those pressures while continuing brand investment. Clorox is also focused on improving market share and integrating GOJO through the Clorox Purell ProCare platform.

Recent Insider Transactions

The latest 10 reported insider transactions were direct stock awards rather than open-market purchases or sales. Their combined reported value was approximately $17.0 million, while the separate six-month summary recorded zero purchase and zero sale transactions and total insider holdings of 838.05 thousand shares.

Because these transactions were compensation-related grants, they do not indicate that executives purchased shares in the open market.

Risks Investors Need to Watch

• Input-cost pressure: Commodity, manufacturing and logistics costs reduced quarterly gross margin, and the updated full-year outlook assumes higher-than-normal inflation and negative mix.
• Dependence on favorable comparisons: About 18 points of quarterly organic growth came from lapping the ERP-related inventory drawdown. Growth will become more dependent on underlying volume, pricing and mix once that comparison fades.
• GOJO integration: The acquisition drove 15 points of quarterly sales growth, but it also introduced inventory step-up charges and integration expenses. Clorox expects about $0.29 per share of related costs in fiscal 2027.
• Higher financing costs: Interest expense increased to $52 million from $23 million, while short- and long-term borrowings remained substantial at quarter-end.

Summary

Clorox began fiscal 2027 with higher sales, earnings and operating cash flow, but the quarter benefited substantially from GOJO and the comparison with the prior-year ERP disruption. The decline in gross margin and management’s expectation for adjusted EPS near the low end of guidance make inflation mitigation, underlying organic demand and GOJO integration the main areas to monitor over the rest of the fiscal year.